Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ArriVent BioPharma, Inc.

NASDAQ: AVBP · Life Sciences · 6 alerts · CIK 1868279

ArriVent BioPharma, Inc. stories on ALFA USA NewsRead the news →
Share price
$11.56Close, Nov 16
Market cap
$598M
Shares outstanding
51.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ArriVent BioPharma, Inc. filings on SEC EDGAR ↗

4:21 PM ET 10-Q
Financial Results

ArriVent BioPharma Q3 2026 Results: Net Loss of $40.3M, Loss Widens

ArriVent BioPharma reported collaboration revenue of $5.0 million for the nine months ended September 30, 2026, compared to zero in the prior year. Despite this, the company saw a net loss of $133.5 million driven by $118.9 million in research and development expenses. Cash and short-term investments increased to $393.2 million, bolstered by $199.6 million in net proceeds from common stock issuances.

Key figure
Net loss $40.3M
4:06 PM ET 8-K
Financial Results

ArriVent BioPharma Financial Results

ArriVent BioPharma reported Q3 2026 financial results, highlighting a cash position of $393.2 million and progress in its Phase 3 ALPACCA study. The company also announced the retirement of Stuart Lutzker, M.D., Ph.D., as President of R&D, with Chief Medical Officer Priti Patel, M.D., assuming leadership of the R&D function.

Term
Q3 2026

“Enrollment remains on track for our global Phase 3 ALPACCA trial in first line EGFR PACC mutant NSCLC patients. While FURVENT did not meet its primary endpoint, firmonertinib demonstrated clear antitumor activity, with an efficacy and safety profile consistent with prior studies.”

Bing Yao, Ph.D., CEO of ArriVent

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.